0H8E Stock Overview An in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Accelerate Diagnostics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Accelerate Diagnostics Historical stock prices Current Share Price US$1.37 52 Week High US$1.98 52 Week Low US$0.85 Beta 0.61 1 Month Change 17.60% 3 Month Change -30.63% 1 Year Change 14.36% 3 Year Change -95.19% 5 Year Change n/a Change since IPO -99.54%
Recent News & Updates
Accelerate Diagnostics Receives Non-Compliance Letter Regarding Nasdaq MVLS Requirement Jan 30
Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? System Oct 01
Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical Trial Aug 09
Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq May 01
Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024 Apr 12 See more updates
Accelerate Diagnostics Receives Non-Compliance Letter Regarding Nasdaq MVLS Requirement Jan 30
Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? System Oct 01
Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical Trial Aug 09
Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq May 01
Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024 Apr 12
Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC Mar 06 Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust Jan 25
Accelerate Diagnostics, Inc. has completed a Composite Units Offering. Jan 21 Accelerate Diagnostics, Inc. has completed a Composite Units Offering. Jan 20
Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market Jul 11
Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.15 loss in 3Q 2021) Mar 07
Insufficient new directors Mar 01
Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement Jan 12
Accelerate Diagnostics Submits 510(K) Application to FDA for Gram-Negative Menu Expansion and Breakpoint Updates for the Accelerate Phenotest(R) BC Kit Dec 20
Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer Dec 16
Accelerate Diagnostics, Inc. Provides Earnings Guidance for the Year 2022 Nov 15
Insider recently bought US$80k worth of stock Aug 31
Accelerate Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $35 million. Aug 20
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.35 loss in 2Q 2021) Aug 16
Accelerate Diagnostics Announces Commercialization of its Accelerate Arc System Having Completed IVD Registration with FDA May 18
First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.41 loss in 1Q 2021) May 17
Accelerate Diagnostics, Inc., Annual General Meeting, May 12, 2022 Apr 08
Accelerate Diagnostics, Inc. Announces Launch of Accelerate Arc™ Module and BC Kit Mar 29
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 09
Accelerate Diagnostics, Inc. Elects Wayne C. Burris as Member of the Board Feb 04
Insider recently bought US$66k worth of stock Feb 02
Independent Director recently bought US$524k worth of stock Jan 21
Independent Director recently bought US$196k worth of stock Jan 16
Accelerate Diagnostics, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2021 Jan 14
Independent Director recently bought US$277k worth of stock Jan 06
Independent Director recently bought US$369k worth of stock Dec 24
Independent Director recently bought US$606k worth of stock Nov 25
Accelerate Diagnostics, Inc. Announces New Accelerate Pheno System Multi-Center Study Published in Clinical Infectious Diseases Nov 24
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020) Nov 10
Accelerate Diagnostics, Inc. announced that it has received $1.55 million in funding Oct 01
Independent Director recently bought US$1.0m worth of stock Sep 30
Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020) Aug 12
Accelerate Diagnostics, Inc. to present New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits at ECCMID 2021 Jul 01
First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.39 loss in 1Q 2020) May 08
Accelerate Diagnostics, Inc. Announces Roland D. Diggelmann Decision Not to Stand for Re-Election to Its Board Mar 21
Full year 2020 earnings released: US$1.40 loss per share (vs US$1.55 loss in FY 2019) Feb 25
Revenue misses expectations Feb 25 Shareholder Returns 0H8E GB Medical Equipment GB Market 7D 0% -1.9% 2.1% 1Y 14.4% -6.7% 12.7%
See full shareholder returns
Return vs Market: 0H8E exceeded the UK Market which returned 12.7% over the past year.
Price Volatility Is 0H8E's price volatile compared to industry and market? 0H8E volatility 0H8E Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.7%
Stable Share Price: 0H8E's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0H8E's volatility change over the past year.
About the Company Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Show more Accelerate Diagnostics, Inc. Fundamentals Summary How do Accelerate Diagnostics's earnings and revenue compare to its market cap? 0H8E fundamental statistics Market cap US$30.80m Earnings (TTM ) -US$53.45m Revenue (TTM ) US$11.91m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0H8E income statement (TTM ) Revenue US$11.91m Cost of Revenue US$9.02m Gross Profit US$2.89m Other Expenses US$56.34m Earnings -US$53.45m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.13 Gross Margin 24.25% Net Profit Margin -448.85% Debt/Equity Ratio -119.6%
How did 0H8E perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/11 00:37 End of Day Share Price 2025/01/28 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Accelerate Diagnostics, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Sean Lavin BTIG Garrett Nelson CFRA Equity Research Alexander Nowak Craig-Hallum Capital Group LLC
Show 3 more analysts 
